Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News GT Biopharma Inc GTBP

Healthcare Biotechnology Diagnostics & Research
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein immune cell engager technology platforms. It develops GTB-3650, which is in preclinical studies that target CD33 on the... see more

Current News (NDAQ:GTBP)

GT Biopharma Announces IND Submission for GTB-5550 TriKE®, a B7-H3-targeted natural killer (NK) cell engager for B7-H3 expressing solid tumor cancers

GlobeNewswire 5 days ago

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials

ACCESS Newswire November 19, 2025

GT Biopharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire November 14, 2025

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

GlobeNewswire October 23, 2025

GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies

GlobeNewswire October 8, 2025

GT Biopharma to Participate in the Centurion One Capital 3rd Annual Bahamas Summit

GlobeNewswire October 6, 2025

GT Biopharma to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

GlobeNewswire September 4, 2025

GT Biopharma Reports Second Quarter 2025 Financial Results

GlobeNewswire August 14, 2025

GT Biopharma Advances into Cohort 3 of GTB-3650 Phase 1 Trial Following Safety Review of Cohort 2

GlobeNewswire August 11, 2025
View More News ››

Opinion & Analysis (NDAQ:GTBP)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GTBP)

GT Biopharma ($GTBP) CEO on Expanding Into Solid Tumors and

Solid tumors represent one of the largest and most challenging areas in cancer treatment. In this interview, GT Biopharma (NASDAQ: GTBP...
PRCStockMan - December 19, 2025

GT Biopharma, Inc. (NASDAQ:GTBP) Offers

GT Biopharma, Inc. (NASDAQ:GTBP) Offers Near-Term Catalyst Opportunity with Advancing Phase 1 Trials  ...
PRCStockMan - November 24, 2025

GT Biopharma Reports Third Quarter 2025 Financial Results

SAN FRANCISCO, CALIFORNIA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno...
PRCStockMan - November 21, 2025

GT Biopharma's ($GTBP) Next-Gen Immunotherapy & Clinical Pr

A breakthrough that could reshape cancer treatment. GT Biopharma (NASDAQ: GTBP) is advancing its next generation TriKE® platform, an...
PRCStockMan - November 14, 2025

Buy buddy buy because it's going to go up today

So that you guys should get your shares as soon as possible otherwise
coolfooldumbguy - February 25, 2025

GT Biopharma, Inc. (NASDAQ:GTBP): Advancing Innovative Immun

http://beyondspx.com/2024/08/01/gt-biopharma-inc-nasdaqgtbp-advancing-innovative-immuno-oncology-therapies/
MikeTester - August 2, 2024
View more Bullboard ››

SEGO Resources Inc.

SEGO Resources Inc.

Sego Resources Inc., an exploration stage company, engages in the acquisition, exploration, and evaluation of mineral ...
View More »

Podcasts